FDA sets up new drug safety Web site

Article

The FDA set up a new Web page to provide postmarket drug safety information to patients and providers.

The Food and Drug Administration (FDA) set up a new Web page to provide postmarket drug safety information to patients and providers, American Medical News (11/17/08) reported. The Web site, http://www.fda.gov/cder/drugsafety.htm, was created under the requirements of the FDA Amendments Act of 2007 and enacted last fall to correct drug safety problems.

The site provides links to a variety of information, including drug labeling; medications that have risk evaluation and mitigation strategies; FDA-required postmarket studies and clinical trials of approved products; registry of federally and privately supported clinical trials; and the latest safety information. Included are an index to drug-specific information, drug safety announcements, medical product safety information from MedWatch, and new safety information identified by the Adverse Event Reporting System. Site users also can link to MedWatch, information about warnings and recalls, regulations and guidance documents, general health information, and consumer and professional articles about using medicines safely.

Recent Videos
Self-collection and extended genotyping advance cervical cancer screening | Image Credit: linkedin.com.
New trends in cervical cancer screening: Self-collection and barriers to adherence | Image Credit: linkedin.com.
Kameelah Phillips, MD, FACOG, NCMP, is featured in this series.
Kameelah Phillips, MD, FACOG, NCMP, is featured in this series.
HPV self-collection: Benefits, limitations, and future implications | Image Credit: forhers.com
Improving pediatric HPV vaccination rates: Early initiation and addressing disparities | Image Credit: blog.nemours.org.
New cervical cancer screening guidelines: What practitioners needs to know | Image Credit: forhers.com
COVID-19 Therapy Roundtable: Focusing on inpatient care
Related Content
© 2025 MJH Life Sciences

All rights reserved.